Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + lenvatinib + microbiota transplantation in advanced colorectal cancer
ChiCTR2200056089Phase 2Not yet recruiting
- Sponsor
- Changzhi People's Hospital
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of nivolumab and lenvatinib in colorectal cancer (CRC), sponsored by Changzhi People's Hospital. Primary endpoint: Objective Response Rate. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
nivolumablenvatinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2200056089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056089.